| Jun 1, 2026 | finance.yahoo.com | NurExone Announces First Quarter 2026 Financial Results and Provides Corporate Update |
| May 19, 2026 | finance.yahoo.com | NurExone Receives Notice of Patent Grant in South Korea Covering ExoPTEN Technology |
| May 14, 2026 | finance.yahoo.com | NurExone Advances to Stage 2 of EU-Backed EIT Health Catapult Programme 2026 |
| Apr 27, 2026 | finance.yahoo.com | Australian Patent Granted to NurExone Covering Stem Cell-Derived Exosome Production |
| Apr 17, 2026 | finance.yahoo.com | NRXBF Worth a Look at This Stage |
| Apr 16, 2026 | finance.yahoo.com | NurExone Biologic Inc. Announces Fourth Quarter and Full-Year 2025 Financial Results and Provides Corporate Update |
| Apr 10, 2026 | finance.yahoo.com | NurExone to Participate in Water Tower Research Insights Conference on April 14, 2026 |
| Apr 7, 2026 | finance.yahoo.com | NurExone Biologic’s U.S. Subsidiary Exo-Top and Florida-Based BioXtek Sign Strategic LOI for Exosome Manufacturing and Commercialization |
| Apr 1, 2026 | finance.yahoo.com | NurExone Receives First Place in Healthcare at BOLD Awards VII and Engages Investor Brand Network to Support Awareness Strategy |
| Mar 26, 2026 | finance.yahoo.com | NurExone Strengthens U.S. Manufacturing Strategy Through Exo-Top Sublicense Agreement |
| Mar 11, 2026 | finance.yahoo.com | NurExone Announces Corporate Updates |
| Feb 27, 2026 | finance.yahoo.com | NurExone to Showcase Its Regenerative Medicine Platform at NANO.IL.2026 and Advanced Therapies Congress in March 2026 and Provides Corporate Update |
| Feb 10, 2026 | finance.yahoo.com | NurExone Biologic Advances Manufacturing and Regulatory Roadmap with Independent Batch Consistency Results for Exosome Production |
| Jan 30, 2026 | finance.yahoo.com | NurExone Appoints Eyal Gabbai to Board, Adding Large-Scale Healthcare System and Capital Markets Expertise |
| Dec 22, 2025 | finance.yahoo.com | NRXBF Keeps Proving its Treatment is Superior |
| Dec 19, 2025 | finance.yahoo.com | NurExone Reports Anti-Inflammatory Activity of Its Exosomes in Lab Analysis |
| Dec 12, 2025 | finance.yahoo.com | NurExone Plans Small-Scale of ExoPTEN Clinical Manufacturing in Preparation for FUTURE First in Human USE Pathways |
| Dec 1, 2025 | finance.yahoo.com | NRXBF Advances Toward Breakthrough Treatments |
| Nov 28, 2025 | finance.yahoo.com | NurExone Biologic Inc. Announces Third Quarter 2025 Financial Results and Provides Corporate Update |
| Nov 12, 2025 | finance.yahoo.com | NurExone Secures over C$3.18 Million Through Accelerated Warrant Exercises |
| Nov 3, 2025 | finance.yahoo.com | NurExone Accepted into ARMI’s BioFab Startup Lab Strengthening U.S Position in Regenerative Manufacturing |
| Oct 27, 2025 | finance.yahoo.com | CEO Chat with Dr. Lior Shaltiel, CEO of NurExone Biologic Inc. |
| Oct 21, 2025 | finance.yahoo.com | NurExone Invited Presenter at Precision EV Forum in Cambridge, UK |
| Oct 13, 2025 | finance.yahoo.com | NRXBF Treatment Restores Sight |
| Oct 8, 2025 | finance.yahoo.com | NurExone Demonstrates Reproducible, Dose-Dependent Vision Recovery in Preclinical Glaucoma Model |
| Sep 16, 2025 | finance.yahoo.com | NurExone Planning to Establish First U.S. Commercial Manufacturing Facility in Indiana |
| Sep 11, 2025 | finance.yahoo.com | NurExone Biologic Announces Corporate Updates including Israel Patent Grant and Private Placement Closing |
| Sep 10, 2025 | finance.yahoo.com | NRXBF Gets Patent for Exciting Cell Technology |
| Sep 8, 2025 | finance.yahoo.com | NurExone Receives U.S. Patent Allowance for Exosome Manufacturing, Strengthening Supply Chain Readiness |
| Aug 28, 2025 | finance.yahoo.com | NurExone Biologic Inc. Announces Second Quarter 2025 Financial Results |
| Aug 20, 2025 | finance.yahoo.com | NurExone Biologic Announces Preclinical Evidence of Structural Repair in Injured Spinal Cord Tissue following ExoPTEN Treatment |
| Aug 11, 2025 | finance.yahoo.com | NRXBF Treatment Shows Remarkable Treatment Properties |
| Aug 8, 2025 | finance.yahoo.com | NurExone’s Exosomes Show Stronger Healing Potential Than Industry Standard |
| Jul 25, 2025 | finance.yahoo.com | NurExone Biologic Finalist in Falling Walls Venture 2025 Global Platform Showcasing The World’s Most Promising Science-Based Start-Ups |
| Jul 9, 2025 | finance.yahoo.com | NRXBF Treatment Restores Mobility to Spinal Injury Patients |
| Jul 8, 2025 | finance.yahoo.com | New ExoPTEN Preclinical Study Indicates Significant Improvement in Walking Quality in Spinal Cord Injury Model |
| Jun 20, 2025 | finance.yahoo.com | NurExone Advances U.S. Growth Strategy with Acceptance into Prestigious ARMI HealthTech Hub Accelerator and Provides Corporate Update |
| Jun 4, 2025 | finance.yahoo.com | NurExone Strengthens Path to Clinical Trials for ExoPTEN with New Manufacturing Process Validation |
| May 30, 2025 | finance.yahoo.com | NurExone Announces Clinical Trial Plans for Acute Spinal Cord Injury Therapy at Annual Meeting of American Spinal Injury Association |
| May 27, 2025 | finance.yahoo.com | NurExone Biologic Inc. Announces First Quarter 2025 Financial Results and Provides Corporate Update |
| May 8, 2025 | finance.yahoo.com | NurExone Advances Vision Restoration Strategy with Preclinical Data Presentation at the Association for Research in Vision and Ophthalmology (ARVO) 2025 |
| May 2, 2025 | finance.yahoo.com | NurExone Expands European Engagement with Investor Events in Germany and Switzerland |
| Apr 24, 2025 | finance.yahoo.com | NurExone to Showcase Breakthrough in Facial Nerve Regeneration at ISEV 2025 |
| Apr 22, 2025 | finance.yahoo.com | NurExone Appoints Biotech Industry Leader - Jacob Licht to Lead U.S. Operations and Exo-Top Manufacturing Expansion and Completes Continuance into Ontario |
| Apr 10, 2025 | finance.yahoo.com | NRXBF Enters Crucial Stage in Good Shape |
| Apr 9, 2025 | finance.yahoo.com | NurExone Biologic Inc. Announces Fourth Quarter and Full-Year 2024 Financial Results and Provides Corporate Update |
| Apr 4, 2025 | finance.yahoo.com | NurExone Biologic Announces U.S. Uplisting Intention and Closes C$2.3 Million Private Placement |
| Mar 17, 2025 | finance.yahoo.com | NRXBF Test Results Bolster Prospects |
| Mar 14, 2025 | finance.yahoo.com | ExoPTEN Preclinical Study Demonstrates Significant Potential for Enhancing Motor Function, Blood Flow, and Spinal Cord Injury Recovery |
| Mar 10, 2025 | finance.yahoo.com | NurExone Biologic Recognized as a 2025 TSX Venture 50(TM) Top Performing Stock |
| Feb 27, 2025 | finance.yahoo.com | NurExone Biologic to Present at MIXiii 2025; Professor Michael Belkin, Head of NurExone Ophthalmology Project, to Receive Lifetime Achievement Award |
| Feb 20, 2025 | finance.yahoo.com | NRXBF Pushing into US Market |
| Feb 19, 2025 | finance.yahoo.com | NurExone Biologic Recognized as a 2025 TSX Venture 50™ Top Performing Stock |
| Feb 14, 2025 | finance.yahoo.com | NurExone Biologic Continues Expansion of U.S. Presence and Awareness with Prestigious Conference Presentation |
| Feb 5, 2025 | finance.yahoo.com | NurExone Forms Exo-Top Inc. in the U.S. for Exosome Manufacture and Commercialization |
| Jan 21, 2025 | finance.yahoo.com | NurExone Secures C$1.2 Million through Warrant Exercises and Completion of Private Placement and Appoints New R&D Director |
| Jan 8, 2025 | finance.yahoo.com | NurExone Biologic Secures Master Cell Bank |
| Dec 9, 2024 | finance.yahoo.com | NRXBF Announces Important Test Results |
| Dec 6, 2024 | finance.yahoo.com | NurExone Announces Promising Preclinical Results in Restoring Vision After Optic Nerve Damage |
| Dec 3, 2024 | finance.yahoo.com | Presenting on the Emerging Growth Conference 77 Day 1 on December 4th Register Now |
| Nov 29, 2024 | finance.yahoo.com | NRXBF: Promising Company Releases Results |
| Nov 27, 2024 | finance.yahoo.com | NurExone Reports Third Quarter 2024 Financial Results and Provides Corporate Update |
| Nov 14, 2024 | finance.yahoo.com | NRXBF Gains Another Governmental Designation |
| Nov 13, 2024 | finance.yahoo.com | NurExone Secures EMA Orphan Status for ExoPTEN in Spinal Cord Injury |
| Nov 13, 2024 | finance.yahoo.com | NurExone Biologic Secures EMA Orphan Status for ExoPTEN in Spinal Cord Injury, Accelerating Pathway to European Markets |
| Nov 1, 2024 | finance.yahoo.com | NurExone Biologic Closes Final Tranche of Non-Brokered Private Placement and Provides Corporate Update |
| Oct 31, 2024 | finance.yahoo.com | NRx Pharmaceuticals added to Emerging Growth Conference 76 on October 31 and Update to Schedule |
| Oct 30, 2024 | finance.yahoo.com | Presenting on the Emerging Growth Conference 76 Day 2 on October 31 Register Now |
| Oct 29, 2024 | finance.yahoo.com | Presenting on the Emerging Growth Conference 76 Day 1 on October 30 Register Now |
| Oct 23, 2024 | finance.yahoo.com | NurExone’s Regenerative Medicine Therapies To Be Recognized at Fall Conferences in the USA |
| Oct 2, 2024 | finance.yahoo.com | Initiating Coverage of NRXBF |
| Sep 26, 2024 | finance.yahoo.com | NurExone Biologic Announces Private Placement of up to $2M and Closes First Tranche for $1.61M |
| Sep 12, 2024 | finance.yahoo.com | NurExone Biologic Extends Global Reach with Presentations at Industry-Leading Conferences |
| Sep 6, 2024 | finance.yahoo.com | NurExone Demonstrates Extended Therapeutic Window of ExoPTEN Post Spinal-Cord Injury in Preclinical Study |
| Aug 28, 2024 | finance.yahoo.com | NurExone Reports Second Quarter 2024 Financial Results and Provides Corporate Update |
| Aug 23, 2024 | finance.yahoo.com | NurExone Biologic Invited to Present Groundbreaking ExoPTEN Therapy at Prestigious September Conferences |
| Aug 15, 2024 | finance.yahoo.com | NurExone Biologic Achieves Key Milestone in Support of Robust Exosome Manufacturing Process |
| Aug 9, 2024 | finance.yahoo.com | NurExone's ExoPTEN, loaded with siRNA, Demonstrates Ability to Target Injury and Inflammation Sites – New Study |
| Aug 1, 2024 | finance.yahoo.com | NurExone Announces the Transfer of Manufacturing of the Active Element in ExoPTEN Drug to a Commercial GMP Manufacturer |
| Jul 29, 2024 | finance.yahoo.com | NurExone Announces Further Expansion of ExoPTEN Patent Coverage |
| Jul 17, 2024 | finance.yahoo.com | Promising Preliminary Results in Optic Nerve Recovery Study of NurExone’s first product ExoPTEN for Glaucoma |
| Jul 17, 2024 | finance.yahoo.com | Presenting on the Emerging Growth Conference 73 Day 2 on July 18 Register Now |
| Jul 5, 2024 | finance.yahoo.com | Updates from NurExone: Growth Conference Presentation and Website Relaunch |
| Jun 28, 2024 | finance.yahoo.com | NurExone’s ExoPTEN Being Studied as Glaucoma Treatment for US$3.4 Billion Market |
| Jun 21, 2024 | finance.yahoo.com | On Path to First-in-Human Study, NurExone Engages Prominent Expert in Biological Drug Development |
| Jun 11, 2024 | finance.yahoo.com | NurExone Announces Expansion of ExoPTEN Patent Coverage with Notice of Allowance for Japanese Patent Application |
| Jun 4, 2024 | finance.yahoo.com | NurExone Announces Voting Results from 2024 Annual Meeting of Shareholders |
| May 31, 2024 | finance.yahoo.com | Is NurExone Biologic (CVE:NRX) In A Good Position To Deliver On Growth Plans? |
| May 29, 2024 | finance.yahoo.com | NurExone Reports First Quarter 2024 Financial Results and Provides Corporate Update, moving forward with FDA guidelines for the Human Trials |
| May 17, 2024 | finance.yahoo.com | NurExone Welcomes Biopharma Exec Dr. Ram Petter to Drive Strategic Collaborations |
| Apr 25, 2024 | finance.yahoo.com | NurExone Biologic Inc. Announces Strategic Expansion to US Financial Markets with Approval of OTCQB Listing Application and DTC Eligibility |
| Apr 19, 2024 | finance.yahoo.com | NurExone Presenting on Revolutionary Spinal Cord Injury Therapy at European Conference on Exosomes and Regenerative Medicine |
| Apr 2, 2024 | finance.yahoo.com | NurExone Reports Fourth Quarter and Year Ended December 31, 2023 Financial Results and Provides Company Update |
| Mar 27, 2024 | finance.yahoo.com | Gross Proceeds Close of $4M CAD Generated for NurExone From Warrants Exercise |
| Mar 22, 2024 | finance.yahoo.com | In Preparation for Expected Human Clinical Trials, NurExone Signs Agreement for Large Scale Preclinical Testing for Its Spinal Cord Injury Therapy, ExoPTEN |
| Mar 15, 2024 | finance.yahoo.com | NurExone's Strategic Update: Submission of OTCQB Listing Application to Initiate US financial presence |
| Mar 8, 2024 | finance.yahoo.com | NurExone establishing State-of-the-Art Research and Development Facility in Haifa, Israel |
| Mar 1, 2024 | finance.yahoo.com | NurExone Presenting Novel Regulatory Pathways for Exosomes Therapies at Global Summit |
| Feb 20, 2024 | finance.yahoo.com | NurExone’s Intellectual Property Portfolio Expands |
| Feb 14, 2024 | finance.yahoo.com | NurExone Launches Licensing Efforts for ExoTherapy Platform |